Evidence map›Paper›PMID 42376477›Full record

ArticleJournal of pharmaceutical analysis2026

M1-NP1 interfering-peptide inhibits cancer cell proliferation and migration by targeting the transcription factor FOXM1.

Chaozhu Pei, Ziwu Xu, Min Ouyang, Huitong Bu, Zhenyu Zou, Yuting Ma, Zhengqing Zhu, Yan Chen, Li Yu, Mingmin Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chaozhu PeiState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Ziwu XuState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Min OuyangState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Huitong BuState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Zhenyu ZouState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Yuting MaState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Zhengqing ZhuState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Yan ChenState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Li YuState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Mingmin HuangState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.
Yongjun TanState Key Laboratory of Chemo and Biosensing, College of Biology, Hunan Research Center of the Basic Discipline for Cell Signaling, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, 410082, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple cancers overexpress forkhead (FOX) box M1 (FOXM1), a transcription factor (TF) that holds great promise for developing cancer drugs. Herein, through yeast-two-hybrid (Y2H) screening, we obtained a novel FOXM1-targeting peptide M1-NP1, which significantly inhibited the cell cycle and migration of cancer cells. Mechanistically, M1-NP1 bound to the C-terminal region of FOXM1 and disrupted its interactions with the cell cycle-related kinase polo-like kinase 1 (PLK1) and the transcriptional co-activator cyclic adenosine monophosphate (AMP) response element-binding protein (CREB) binding protein (CBP), thus inhibiting FOXM1 transcriptional activities. Additionally, M1-NP1 affected FOXM1 distribution in cells, preventing FOXM1 from infiltrating the nucleus to exert its effects. Furthermore, M1-NP1 treatment in cancer cells downregulated the gene sets of cell cycle phase transition and upregulated the gene sets of cell adhesion. Moreover, M1-NP1's anti-cancer effects were confirmed in wild-type (WT) mice, without any notable toxic or side effects. In addition to its good safety indications, such as the low levels of immunogenicity and hemolysis, M1-NP1 also exhibited a favorable profile regarding stability and distribution in mice. Overall, M1-NP1 targets FOXM1 for cancer therapy.

Indexed as

FOXM1 transcription factorM1-NP1 interfering-peptideProtein-protein interactionsTargeted cancer therapyYeast-two-hybrid screening

Identifiers

PMID42376477
PMCPMC13312473

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.